All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Common side-effects after Autologous Hematopoietic Stem Cell Transplantation (AHSCT) include pain, poor appetite, fatigue, insomnia, nausea, vomiting and diarrhoea, and are typically managed with pharmacological interventions. However, medicines to control these symptoms can also cause further side-effects leading to a more problematic recovery and reducing patient quality of life.
On 17th September 2017, Gary Deng from the Memorial Sloan Kettering Cancer Center, New York, and colleagues, published a paper in Support Care Cancer to report their findings following a study to explore the use of acupuncture in the management of side-effects after AHSCT in patients with Multiple Myeloma (MM). The authors investigated the use of acupuncture as an integrative non-pharmacological method of improving patient symptoms using a randomized sham-controlled trial.
The trial took place at Memorial Sloan Kettering Cancer Center, New York, between May 2013 and January 2016 and was subject- and evaluator-blind. Patients included in the study (n=60) had a diagnosis of MM and were treated with high-dose melphalan followed by autologous peripheral blood HCT. Patients were randomized to receive either true- or sham-acupuncture. The primary outcome of symptom burden was assessed using the MD Anderson Symptom Inventory (MDASI) and was measured at baseline, during transplantation and on Day 15 and 30 post-transplantation.
The authors concluded that even though there was no significance in the overall symptom scores between the true- and sham-acupuncture groups, it was worth noting that there were statistically significant improvements in nausea, appetite and drowsiness, as well as reduced use of pain medication within the true-acupuncture group. Since the treatment was safe and well tolerated by patients, the study suggests that acupuncture could potentially improve patient quality of life and symptom burden after AHSCT. Further investigation into this integrative treatment in a larger sample size may be useful to further evidence the benefit of acupuncture in these patients.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox